Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
P/E ratio for Novo Nordisk A/S (NVO)
P/E ratio as of 2023: 37.40
According to Novo Nordisk A/S's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 37.40. At the end of 2022 the company had a P/E ratio of 38.27.
P/E ratio history for Novo Nordisk A/S from 1985 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 37.40 |
| 2022 | 38.27 |
| 2021 | 35.35 |
| 2020 | 23.63 |
| 2019 | 23.57 |
| 2018 | 19.06 |
| 2017 | 21.70 |
| 2016 | 17.02 |
| 2015 | 29.57 |
| 2014 | 25.85 |
| 2013 | 21.26 |
| 2012 | 24.03 |
| 2011 | 21.83 |
| 2010 | 25.35 |
| 2009 | 18.48 |
| 2008 | 8.66 |
| 2007 | 12.01 |
| 2006 | 11.86 |
| 2005 | 9.94 |
| 2004 | 10.01 |
| 2003 | 8.43 |
| 2002 | 8.66 |
| 2001 | 15.27 |
| 2000 | 15.64 |
| 1999 | 15.45 |
| 1998 | 13.25 |
| 1997 | 16.64 |
| 1996 | 11.50 |
| 1995 | 9.26 |
| 1994 | 7.54 |
| 1993 | 8.75 |
| 1992 | 8.09 |
| 1991 | 16.53 |
| 1990 | 7.01 |
| 1989 | 8.49 |
| 1988 | 10.43 |
| 1987 | 9.19 |
| 1986 | 8.45 |
| 1985 | 7.18 |